Business

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2

articleBiogen Inc.June 18, 20253/company/biogen-inc/news/biogen-initiates-phase-3-pediatric-study-of-omaveloxolone-for-the-treatment-of-friedreich-ataxia

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

About this update from Biogen Inc.

[{"type":"text","content":"Global Phase 3 BRAVE study will evaluate the efficacy and safety of omaveloxolone in children 2 to","length":118,"tagName":"div"}]

More updates from Biogen Inc.